Omeros (OMER) Stock Price, News & Analysis

Company Overview

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery. Omidria is marketed in the United States through a partnership with Mallinckrodt Pharmaceuticals, with additional regulatory filings underway in selected international markets. The approval and commercialization of Omidria marked the company’s transition from a pure-research organization to a commercial stage biopharma company.

The company’s lead clinical candidate, narsoplimab (OMS721), is a human monoclonal antibody that inhibits mannan-binding lectin-associated serine protease-2 (MASP-2), a key enzyme in the lectin pathway of complement activation. Narsoplimab is being evaluated in rare, life-threatening disorders such as hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-TMA) and IgA nephropathy. In addition, Omeros has several small-molecule programs in development, including P2X7 receptor antagonists for neuropathic pain and addiction and selective kappa opioid receptor modulators for mood disorders.

Headquartered in Seattle, Washington, Omeros was founded in 1994 and completed its initial public offering in 2010. Under the leadership of founder and CEO Gregory A. Demopulos, M.D., the company has grown to include research and development facilities in both the United States and Europe, supporting global clinical trials and regulatory activities. Omeros continues to expand its pipeline through in-house discovery efforts and strategic collaborations aimed at bringing novel therapies to patients worldwide.

Key Stats

• Today's Range: $4.41 to $4.69
• 50-Day Range: $3.61 to $4.61
• 52-Week Range: $2.95 to $13.60
• Volume: 668,724 shs
• Average Volume: 907,406 shs
• Market Capitalization: $302.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Omeros Stock Analysis - MarketRank™

Omeros scored higher than 72% of companies evaluated by MarketBeat, and ranked 287th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omeros has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Omeros has a consensus price target of $18.00, representing about 305.4% upside from its current price of $4.44.

Amount of Analyst Coverage

Omeros has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Omeros are expected to grow in the coming year, from ($3.09) to ($1.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omeros is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omeros is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.84% of the outstanding shares of Omeros have been sold short.

Short Interest Ratio / Days to Cover

Omeros has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Omeros has recently increased by 2.74%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omeros does not currently pay a dividend.

Dividend Growth

Omeros does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.30

Percentage of Shares Shorted

19.84% of the outstanding shares of Omeros have been sold short.

Short Interest Ratio / Days to Cover

Omeros has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Omeros has recently increased by 2.74%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.44

News Sentiment

Omeros has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Omeros this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for OMER on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Omeros to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Omeros insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.90% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

48.79% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OMER Stock Analysis - Frequently Asked Questions

How have OMER shares performed this year?

Omeros' stock was trading at $9.88 at the start of the year. Since then, OMER shares have decreased by 55.1% and is now trading at $4.44.

How were Omeros' earnings last quarter?

Omeros Corporation (NASDAQ:OMER) issued its earnings results on Thursday, August, 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02. The biopharmaceutical company had revenue of $28.60 million for the quarter, compared to the consensus estimate of $0.31 million.
Read the conference call transcript.

Does Omeros have any subsidiaries?

Omeros subsidiaries include Nura.

How do I buy shares of Omeros?

Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Omeros own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Omeros investors own include JPMorgan Chase & Co. (JPM), Visa (V), AbbVie (ABBV), Meta Platforms (META), NVIDIA (NVDA), QUALCOMM (QCOM) and Global X Nasdaq 100 Covered Call ETF (QYLD).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OMER
• CIK: 1285819
• Web: www.omeros.com
• Phone: (206) 676-5000
• Fax: 206-676-5005
• Employees: 210
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Omeros: $18.00
• High Price Target: $36.00
• Low Price Target: $9.00
• Potential Upside/Downside: +305.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$156.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -55.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.81
• Quick Ratio: 0.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.15) per share
• Price / Book: -1.41

Miscellaneous

• Outstanding Shares: 68,056,000
• Free Float: 59,277,000
• Market Cap: $302.17 million
• Optionable: Optionable
• Beta: 2.32